Novo Nordisk acquires Corvidia

Pharma company Novo Nordisk acquires AstraZeneca spinoff Corvidia Therapeutics for $2.1B.



“Sofinnova Partners has played a central role in building this company from the very beginning, leveraging its extensive international network to bring in key hires and providing strategic guidance to advance our scientific work around precision therapies for cardiovascular diseases.”
Mr. de Garidel, CEO of Corvidia

Corvidia’s current lead candidate has shown the ability to reduce risk of major cardiovascular events in individuals suffering from chronic kidney disease.